UCB S.A.
Company Snapshot
Company Overview
The needs of those who suffer from serious illnesses served as the inspiration for UCB S.A., a multinational biopharma company. The company continuously fulfills its promise to enhance the quality of life for those suffering from serious neurological and immunological disorders. The roughly 9,000 employees, who work from headquarters in Belgium and in almost 40 countries worldwide, are the driving force behind this success. Since 1928, the employees of the company have lived out their mission every day by investing heavily in biopharmaceutical research and spearheading innovations that aim to improve the lives of those we serve significantly.
The company has three business operating segments: neurology, immunology, and established brands. In order to address the issues that are important to those who are suffering from serious illnesses, UCB is constantly striving to improve science and embrace new information. It is making use of new technologies and scientific advances in fields like human biology, biomarkers, and genetics.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
UCB S.A. In News
Company's Business Segments
- Immunology : CIMZIA, BIMZELX, EVENITY
- Neurology : BRIVIACT, KEPPRA, FINTEPLA, VIMPAT, RYSTIGGO, NAYZILAM, ZILBRYSQ
- Established Brands : Atarax, Nootropil
Applications/End User Industries
- Biotechnology
- Life Sciences
- Healthcare
- Pharmaceuticals
